Despite widespread use of proton pump inhibitors (PPIs), the incidence of esophageal adenocarcinoma (EAC) continues to rise. PPIs reduce reflux acidity, but only transiently inactivate gastric enzymes. Nonacid reflux, specifically nonacid pepsin, contributes to carcinogenesis in the larynx. Given the carcinogenic potential of pepsin and inefficacy of PPIs to prevent EAC, the presence and effect of pepsin in the esophagus should be investigated.
Methods:
Normal and Barrett’s biopsies from 8 Barrett’s esophagus patients were collected for pepsin analysis via Western blot and reverse transcriptase-polymerase chain reaction (RT-PCR). Human esophageal cells cultured from healthy patients were treated with pepsin (0.01-1 mg/mL; 1-20 hours), acid (pH 4) ± pepsin (5 minutes); real-time RT-PCR, ELISA, and cell migration were assayed.
Results:
Pepsin was detected in all 8 Barrett’s and 4 of 8 adjacent normal specimens. Pepsinogen mRNA was observed in 22 Barrett’s, but not in normal adjacent samples. Pepsin induced PTSG2 (COX-2) and IL-1β expression and cell migration in vitro.
Conclusions:
Pepsin is synthesized by metaplastic, Barrett’s esophageal mucosa. Nonacid pepsin increases metrics of tumorigenicity in esophageal epithelial cells in vitro. These findings implicate refluxed and locally synthesized pepsin in development and progression of EAC and, in part, explain the inefficacy of PPIs in the prevention of EAC.
EverhartJERuhlCE.Burden of digestive diseases in the United States part I: overall and upper gastrointestinal diseases. Gastroenterology. 2009;136:376-386.
2.
ZhangY.Epidemiology of esophageal cancer. World J Gastroenterol. 2013;19:5598-5606.
3.
DulaiGSGuhaSKahnKLGornbeinJWeinsteinWM.Preoperative prevalence of Barrett’s esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology. 2002;122:26-33.
4.
ChoudhryMNSoranHZiglamHM.Overuse and inappropriate prescribing of proton pump inhibitors in patients with Clostridium difficile-associated disease. QJM. 2008;101:445-448.
5.
ZinkDAPohlmanMBarnesMCannonME.Long-term use of acid suppression started inappropriately during hospitalization. Aliment Pharmacol Ther. 2005;21:1203-1209.
6.
PhamCQRegalREBostwickTRKnaufKS.Acid suppressive therapy use on an inpatient internal medicine service. Ann Pharmacother. 2006;40:1261-1266.
7.
BrownLMDevesaSSChowWH.Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst. 2008;100:1184-1187.
Hvid-JensenFPedersenLFunch-JensenPDrewesAM.Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett’s oesophagus: a nationwide study of 9883 patients. Aliment Pharmacol Ther. 2014;39:984-991.
10.
HunterJG.Antireflux surgery for dysplastic Barrett’s esophagus. World J Surg. 2015;39:595-596.
11.
BurnatGRauTElshimiEHahnEGKonturekPC.Bile acids induce overexpression of homeobox gene CDX-2 and vascular endothelial growth factor (VEGF) in human Barrett’s esophageal mucosa and adenocarcinoma cell line. Scand J Gastroenterol. 2007;42:1460-1465.
12.
KazumoriHIshiharaSRumiMAKKadowakiYKinoshitaY.Bile acids directly augment caudal related homeobox gene Cdx2 expression in oesophageal keratinocytes in Barrett’s epithelium. Gut. 2006;55:16-25.
13.
KellyEASamuelsTLJohnstonN.Chronic pepsin exposure promotes anchorage-independent growth and migration of a hypopharyngeal squamous cell line. Otolaryngol Head Neck Surg. 2014;150:618-624.
14.
JohnstonNYanJCHoekzemaCR. Pepsin promotes proliferation of laryngeal and pharyngeal epithelial cells. Laryngoscope. 2012;122:1317-1325.
15.
JohnstonNWellsCWSamuelsTLBluminJH.Rationale for targeting pepsin in the treatment of reflux disease. Ann Otol Rhinol Laryngol. 2010;119:547-558.
16.
JohnstonNWellsCWSamuelsTLBluminJH.Pepsin in nonacidic refluxate can damage hypopharyngeal epithelial cells. Ann Otol Rhinol Laryngol. 2009;118:677-685.
17.
PearsonJPParikhSOrlandoRC. Reflux and its consequences—the laryngeal, pulmonary and oesophageal manifestations. Conference held in conjunction with the 9th International Symposium on Human Pepsin (ISHP)Kingston-upon-Hull, UK, 21-23 April 2010. Aliment Pharmacol Ther. 2011;33(suppl 1):1-71.
18.
LeeSHSamuelsTBockJMBluminJHJohnstonN.Establishment of an immortalized laryngeal posterior commissure cell line as a tool for reflux research. Laryngoscope. 2015;125:E73-E77. doi:10.1002/lary.24952.
19.
AxfordSESharpNRossPE. Cell biology of laryngeal epithelial defenses in health and disease: preliminary studies. Ann Otol Rhinol Laryngol. 2001;110:1099-1108.
20.
CrapkoMKerschnerJESyringMJohnstonN.Role of extra-esophageal reflux in chronic otitis media with effusion. Laryngoscope. 2007;117:1419-1423.
21.
SamuelsTLJohnstonN.Pepsin as a causal agent of inflammation during nonacidic reflux. Otolaryngol Head Neck Surg. 2009;141:559-563.
22.
JohnstonNWellsCWBluminJHToohillRJMeratiAL.Receptor-mediated uptake of pepsin by laryngeal epithelial cells. Ann Otol Rhinol Laryngol. 2007;116:934-938.
23.
VelaMFCamacho-LobatoLSrinivasanRTutuianRKatzPOCastellDO.Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology. 2001;120:1599-1606.
24.
PalsGErikssonAWPronkJC. Differential expression of pepsinogen isozymogens in a patient with Barrett esophagus. Clin Genet. 1988;34:90-97.
25.
ManglaJ. Acid and pepsin production by Barrett’s epithelium: role of radionuclide imaging in diagnosis. In: SpechlerSJGoyalRK, eds. Barrett’s Esophagus: Pathophysiology, Diagnosis and Management. New York, NY: Elsevier; 1985:49-57.
26.
KahrilasP.What is the cell line giving rise to the columnar mucosa? In: GiuliRTytgatGNJDeMeesterTRGalmicheJP, eds. The Esophageal Mucosa: Epidemiology. Proceedings from the World Organization for Specialized Studies on Diseases of the Esophagus; Paris, France; 2004;186.
27.
AntonioloD.Are parietal and chief cells present in Barrett’s esophagus, and are such cells functional? In: GiuliRTytgatGNJDeMeesterTRGalmicheJP, eds. The Esophageal Mucosa: Epidemiology. Proceedings from the World Organization for Specialized Studies on Diseases of the Esophagus; Paris, France; 2004;208.
28.
JohnstonNDettmarPWLivelyMO. Effect of pepsin on laryngeal stress protein (Sep70, Sep53, and Hsp70) response: role in laryngopharyngeal reflux disease. Ann Otol Rhinol Laryngol. 2006;115:47-58.
29.
FitzgeraldRCAbdallaSOnwuegbusiBA. Inflammatory gradient in Barrett’s oesophagus: implications for disease complications. Gut. 2002;51:316-322.
30.
ChenMHuangJZhuZZhangJLiK.Systematic review and meta-analysis of tumor biomarkers in predicting prognosis in esophageal cancer. BMC Cancer. 2013;13:539.
31.
SouzaRFShewmakeKBeerDGCryerBSpechlerSJ.Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res. 2000;60:5767-5772.
32.
OyamaKFujimuraTNinomiyaI. A COX-2 inhibitor prevents the esophageal inflammation-metaplasia-adenocarcinoma sequence in rats. Carcinogenesis. 2005;26:565-570.
33.
KaurBSKhamneheiNIravaniMNamburuSSLinOTriadafilopoulosG.Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett’s esophagus. Gastroenterology. 2002;123:60-67.
34.
Lao-SirieixPRoyAWorrallCVowlerSLGardinerSFitzgeraldRC.Effect of acid suppression on molecular predictors for esophageal cancer. Cancer Epidemiol Biomarkers Prev. 2006;15:288-293.
35.
FeaginsLAZhangHYHormi-CarverK. Acid has antiproliferative effects in nonneoplastic Barrett’s epithelial cells. Am J Gastroenterol. 2007;102:10-20.
36.
ZhangHYZhangXHormi-CarverKFeaginsLASpechlerSJSouzaRF.In non-neoplastic Barrett’s epithelial cells, acid exerts early antiproliferative effects through activation of the Chk2 pathway. Cancer Res. 2007;67:8580-8587.
